(VIRP) Virbac - Ratings and Ratios
Vaccines, Antibiotics, Parasiticides, Dermatology, Petfood
Description: VIRP Virbac
Virbac SA is a global animal health company that develops, manufactures, and markets a diverse range of products and services for companion and farm animals. The companys product portfolio includes vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, and nutrition products. Virbac serves veterinarians, farmers, and pet owners across multiple regions, including Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific.
From a financial perspective, Virbacs market capitalization stands at approximately €3.05 billion, indicating a mid-cap company with a significant presence in the animal health industry. The companys return on equity (RoE) is 27.80%, suggesting a strong ability to generate profits from shareholder equity. With a price-to-earnings (P/E) ratio of 20.98, Virbacs stock is trading at a reasonable valuation relative to its earnings. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin can be analyzed. For instance, a stable or increasing gross margin could indicate effective pricing strategies and cost management.
To gain a deeper understanding of Virbacs competitive position, its essential to examine the companys research and development (R&D) pipeline, product launches, and market share trends. A strong R&D pipeline can drive future growth, while successful product launches can contribute to revenue increases. Additionally, analyzing Virbacs debt-to-equity ratio and interest coverage ratio can provide insights into the companys financial leverage and ability to meet its financial obligations. By examining these KPIs, investors can make more informed decisions about Virbacs stock.
VIRP Stock Overview
| Market Cap in USD | 3,207m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
VIRP Stock Ratings
| Growth Rating | 11.6% |
| Fundamental | 86.1% |
| Dividend Rating | 52.6% |
| Return 12m vs S&P 500 | -29.3% |
| Analyst Rating | - |
VIRP Dividends
| Dividend Yield 12m | 0.45% |
| Yield on Cost 5y | 0.80% |
| Annual Growth 5y | 15.18% |
| Payout Consistency | 82.1% |
| Payout Ratio | 7.6% |
VIRP Growth Ratios
| Growth Correlation 3m | 2.5% |
| Growth Correlation 12m | -11% |
| Growth Correlation 5y | 26.8% |
| CAGR 5y | 6.61% |
| CAGR/Max DD 3y | 0.22 |
| CAGR/Mean DD 3y | 0.60 |
| Sharpe Ratio 12m | -1.54 |
| Alpha | -20.44 |
| Beta | 0.064 |
| Volatility | 27.05% |
| Current Volume | 4.7k |
| Average Volume 20d | 2.5k |
| Stop Loss | 316.7 (-3%) |
| Signal | -0.85 |
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (266.6m TTM) > 0 and > 6% of Revenue (6% = 158.7m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 7.62pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.35% (prev 35.74%; Δ -21.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 321.5m > Net Income 266.6m (YES >=105%, WARN >=100%) |
| Net Debt (157.4m) to EBITDA (506.9m) ratio: 0.31 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (8.38m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 58.88% (prev 35.13%; Δ 23.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 157.5% (prev 83.54%; Δ 73.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 44.61 (EBITDA TTM 506.9m / Interest Expense TTM 9.15m) >= 6 (WARN >= 3) |
Altman Z'' 4.64
| (A) 0.20 = (Total Current Assets 844.1m - Total Current Liabilities 464.6m) / Total Assets 1.90b |
| (B) 0.08 = Retained Earnings (Balance) 145.3m / Total Assets 1.90b |
| (C) 0.24 = EBIT TTM 408.4m / Avg Total Assets 1.68b |
| (D) 1.38 = Book Value of Equity 1.18b / Total Liabilities 859.2m |
| Total Rating: 4.64 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 86.07
| 1. Piotroski 9.0pt = 4.0 |
| 2. FCF Yield 7.15% = 3.58 |
| 3. FCF Margin 7.72% = 1.93 |
| 4. Debt/Equity 0.26 = 2.47 |
| 5. Debt/Ebitda 0.53 = 2.29 |
| 6. ROIC - WACC 18.59% = 12.50 |
| 7. RoE 27.80% = 2.32 |
| 8. Rev. Trend 93.07% = 4.65 |
| 9. Rev. CAGR 16.77% = 2.10 |
| 10. EPS Trend 9.76% = 0.24 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of VIRP shares?
Over the past week, the price has changed by +0.46%, over one month by -1.21%, over three months by +4.12% and over the past year by -16.33%.
Is Virbac a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VIRP is around 304.85 EUR . This means that VIRP is currently overvalued and has a potential downside of -6.63%.
Is VIRP a buy, sell or hold?
What are the forecasts/targets for the VIRP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 397.6 | 21.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 331.7 | 1.6% |
VIRP Fundamental Data Overview
Market Cap EUR = 2.74b (2.74b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 149.6m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 18.8293
P/S = 1.9575
P/B = 2.6223
Beta = 0.819
Revenue TTM = 2.64b EUR
EBIT TTM = 408.4m EUR
EBITDA TTM = 506.9m EUR
Long Term Debt = 217.7m EUR (from longTermDebt, last quarter)
Short Term Debt = 51.2m EUR (from shortTermDebt, last quarter)
Debt = 268.9m EUR (Calculated: Short Term 51.2m + Long Term 217.7m)
Net Debt = 157.4m EUR (from netDebt column, last quarter)
Enterprise Value = 2.85b EUR (2.74b + Debt 268.9m - CCE 149.6m)
Interest Coverage Ratio = 44.61 (Ebit TTM 408.4m / Interest Expense TTM 9.15m)
FCF Yield = 7.15% (FCF TTM 204.2m / Enterprise Value 2.85b)
FCF Margin = 7.72% (FCF TTM 204.2m / Revenue TTM 2.64b)
Net Margin = 10.08% (Net Income TTM 266.6m / Revenue TTM 2.64b)
Gross Margin = 58.88% ((Revenue TTM 2.64b - Cost of Revenue TTM 1.09b) / Revenue TTM)
Tobins Q-Ratio = 2.42 (Enterprise Value 2.85b / Book Value Of Equity 1.18b)
Interest Expense / Debt = 1.86% (Interest Expense 5.00m / Debt 268.9m)
Taxrate = 30.0% (62.5m / 208.3m)
NOPAT = 285.9m (EBIT 408.4m * (1 - 30.00%))
Current Ratio = 1.82 (Total Current Assets 844.1m / Total Current Liabilities 464.6m)
Debt / Equity = 0.26 (Debt 268.9m / last Quarter total Stockholder Equity 1.04b)
Debt / EBITDA = 0.53 (Net Debt 157.4m / EBITDA 506.9m)
Debt / FCF = 1.32 (Debt 268.9m / FCF TTM 204.2m)
Total Stockholder Equity = 959.0m (last 4 quarters mean)
RoA = 14.01% (Net Income 266.6m, Total Assets 1.90b )
RoE = 27.80% (Net Income TTM 266.6m / Total Stockholder Equity 959.0m)
RoCE = 34.71% (Ebit 408.4m / (Equity 959.0m + L.T.Debt 217.7m))
RoIC = 24.39% (NOPAT 285.9m / Invested Capital 1.17b)
WACC = 5.81% (E(2.74b)/V(3.00b) * Re(6.25%)) + (D(268.9m)/V(3.00b) * Rd(1.86%) * (1-Tc(0.30)))
Shares Correlation 3-Years: 0.0 | Cagr: -0.05%
Discount Rate = 6.25% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 74.53% ; FCFE base≈140.7m ; Y1≈112.3m ; Y5≈75.9m
Fair Price DCF = 168.3 (DCF Value 1.41b / Shares Outstanding 8.38m; 5y FCF grow -24.16% → 3.0% )
Revenue Correlation: 93.07 | Revenue CAGR: 16.77%
Rev Growth-of-Growth: -4.21
EPS Correlation: 9.76 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 164.7